MarketPR
MDMD names David Haddock general counsel as Mary Ann Moore's Pediatrix exit takes formal shapeJul 25MARKETSSSD declares $0.30 quarterly cash dividend, ex-date and record date set for October 1Jul 25MARKETSBLUBF declares CAD 0.04 monthly cash dividend with August 31 ex-dateJul 25CNXCConcentrix CNXC board adopts amended severance plan with 2x change-of-control payout and new standalone benefitJul 24QSIQSI in focus: Quantum-Si receives Nasdaq minimum bid price notice, faces January 19 compliance deadlineJul 24INSPInspire Medical Systems adds AtriCure CEO Michael Carrel to board in July 20 appointmentJul 24MARKETSCapital expenditure in focus as Alphabet raises the AI spending bar, three hyperscalers left to reportJul 24FJETFJET 8-K: Starfighters Space names CBIZ CPAs as auditor with STARLAUNCH program in Critical Design ReviewJul 24BVFLBVFL Q2 print: $0.42 per share, NIM at 4.58% as FHLB debt clearsJul 24MARKETSCAMJF declares JPY 55.0 semi-annual cash dividend, ex-date December 31Jul 24MDMD names David Haddock general counsel as Mary Ann Moore's Pediatrix exit takes formal shapeJul 25MARKETSSSD declares $0.30 quarterly cash dividend, ex-date and record date set for October 1Jul 25MARKETSBLUBF declares CAD 0.04 monthly cash dividend with August 31 ex-dateJul 25CNXCConcentrix CNXC board adopts amended severance plan with 2x change-of-control payout and new standalone benefitJul 24QSIQSI in focus: Quantum-Si receives Nasdaq minimum bid price notice, faces January 19 compliance deadlineJul 24INSPInspire Medical Systems adds AtriCure CEO Michael Carrel to board in July 20 appointmentJul 24MARKETSCapital expenditure in focus as Alphabet raises the AI spending bar, three hyperscalers left to reportJul 24FJETFJET 8-K: Starfighters Space names CBIZ CPAs as auditor with STARLAUNCH program in Critical Design ReviewJul 24BVFLBVFL Q2 print: $0.42 per share, NIM at 4.58% as FHLB debt clearsJul 24MARKETSCAMJF declares JPY 55.0 semi-annual cash dividend, ex-date December 31Jul 24
NewsMacro · MD

MD names David Haddock general counsel as Mary Ann Moore's Pediatrix exit takes formal shape

Pediatrix Medical Group (NYSE: MD) has a new name in the general counsel chair. David Haddock joins as Executive Vice President, General Counsel and Secretary at the Sunrise, Florida-based company, as Mary Ann Moore's departure, first flagged on May 1, 2026, moves from a calendar placeholder to a binding agreement. The separation agreement signed July 21 sets October 31 as Moore's last day with the organization.

By Lena ParkMacro DeskJuly 25, 20262 min readMD
Share

Key takeaways

  • David Haddock has joined Pediatrix Medical Group (NYSE: MD) as Executive Vice President, General Counsel and Secretary.
  • Mary Ann Moore signed a separation agreement on July 21 setting October 31, 2026 as her last day, after her departure was first flagged on May 1, 2026.
  • Pediatrix designates Moore's departure as a termination without cause under her Second Amended and Restated Employment Agreement, though the 8-K lists no dollar amounts.
  • Haddock takes on three of Moore's four titles but not the Chief Administrative Officer role, and the filing does not say how that function will be covered.
  • The 8-K was filed July 24 and signed by CFO Kasandra H. Rossi, with Haddock's appointment disclosed under Regulation FD in the same filing.

Pediatrix Medical Group (NYSE: MD) has a new name in the general counsel chair. David Haddock joins as Executive Vice President, General Counsel and Secretary at the Sunrise, Florida-based company, as Mary Ann Moore's departure, first flagged on May 1, 2026, moves from a calendar placeholder to a binding agreement. The separation agreement signed July 21 sets October 31 as Moore's last day with the organization.

The separation agreement

Moore's exit was already on the books. The May 1 disclosure said she would leave her combined role, which carried the Executive Vice President, General Counsel, Chief Administrative Officer and Secretary titles, before the end of 2026. The July 21 agreement, executed between Moore and PMG Services, Inc., a wholly-owned Pediatrix subsidiary, puts structure around that timeline: Moore serves in an advisory capacity through October 31, then separates completely. Pediatrix designates the departure as a termination without cause under Moore's Second Amended and Restated Employment Agreement with PMG, meaning Moore collects the benefits specified in that contract. The 8-K was filed July 24 and signed by Chief Financial Officer Kasandra H. Rossi. No dollar amounts appear in the document.

What Haddock inherits and what he does not

Haddock's appointment was disclosed under Regulation FD in the same filing. His title is Executive Vice President, General Counsel and Secretary, three of the four designations Moore held. The Chief Administrative Officer title does not appear alongside his name. The 8-K does not address how Pediatrix intends to cover that function or whether the responsibilities fold into an existing role. For investors watching MD's executive composition, that is the question the filing leaves open.

What to watch

October 31, 2026 is the definitive marker: Moore's advisory period closes, and her separation from Pediatrix Medical Group becomes effective on that date. Subsequent proxy filings are the next place to look for Haddock's compensation terms. Any decision on the Chief Administrative Officer vacancy would surface there or in a future 8-K.

About this story

Filed by the macro desk of MarketPR on July 25, 2026. Source: MarketPR. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro

SSD declares $0.30 quarterly cash dividend, ex-date and record date set for October 1

A quarterly cash dividend of $0.30 per share is in focus for SSD, with the ex-dividend date and record date both confirm

Jonah Berg2 min read
02Macro

BLUBF declares CAD 0.04 monthly cash dividend with August 31 ex-date

A monthly cash dividend of CAD 0.04 per share is in focus for BLUBF, with the ex-dividend date and record date both confirmed for August 31, 2026. Payment follows on September 15.

Mateo Fuentes2 min read
03Macro · CNXC

Concentrix CNXC board adopts amended severance plan with 2x change-of-control payout and new standalone benefit

In focus for CNXC holders: Concentrix Corporation's board adopted an Amended and Restated Executive Severance Plan on July 23, replacing the company's existing Change of Control Severance Plan. The revision raises the payout floor for executives terminated during a deal window an

Ines Ferreira2 min read

Frequently asked

Who is replacing Mary Ann Moore as general counsel at Pediatrix?

David Haddock is joining as Executive Vice President, General Counsel and Secretary, taking three of the four titles Moore previously held.

When is Mary Ann Moore's departure effective?

Moore serves in an advisory capacity through October 31, 2026, when her separation from Pediatrix becomes effective.

What happens to the Chief Administrative Officer title Moore held?

Haddock's appointment does not include the Chief Administrative Officer title, and the 8-K does not address how that function will be covered or whether it folds into an existing role.

Was Moore's exit a firing?

Pediatrix designates the departure as a termination without cause under Moore's employment agreement, meaning she collects the benefits specified in that contract.

Where will investors find Haddock's compensation terms?

Subsequent proxy filings are the next place to look for Haddock's compensation terms, along with any decision on the Chief Administrative Officer vacancy.